

Emily A Kendall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2434275/publications.pdf>

Version: 2024-02-01

55
papers

1,199
citations

489802

18
h-index

466096

32
g-index

58
all docs

58
docs citations

58
times ranked

2047
citing authors

#	ARTICLE	IF	CITATIONS
1	Model-Estimated Association Between Simulated US Elementary School-Related SARS-CoV-2 Transmission, Mitigation Interventions, and Vaccine Coverage Across Local Incidence Levels. <i>JAMA Network Open</i> , 2022, 5, e2147827.	2.8	12
2	Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students. <i>JAMA Pediatrics</i> , 2022, 176, 679.	3.3	11
3	When Infections Don't Reflect Infectiousness: Interpreting Contact Investigation Data With Care. <i>Clinical Infectious Diseases</i> , 2021, 73, e3456-e3458.	2.9	6
4	The Epidemiological Importance of Subclinical Tuberculosis. A Critical Reappraisal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 168-174.	2.5	87
5	Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis. <i>BMC Medicine</i> , 2021, 19, 75.	2.3	40
6	Characterization of geographic mobility among participants in facility- and community-based tuberculosis case finding in urban Uganda. <i>PLoS ONE</i> , 2021, 16, e0251806.	1.1	6
7	Reply to Pierce: Subclinical Tuberculosis: Some Flies in the Ointment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1328-1329.	2.5	1
8	Antigen-based Rapid Diagnostic Testing or Alternatives for Diagnosis of Symptomatic COVID-19. <i>Epidemiology</i> , 2021, 32, 811-819.	1.2	11
9	The Spectrum of Tuberculosis Disease in an Urban Ugandan Community and Its Health Facilities. <i>Clinical Infectious Diseases</i> , 2021, 72, e1035-e1043.	2.9	24
10	Achieving a "step change" in the tuberculosis epidemic through comprehensive community-wide intervention: a model-based analysis. <i>BMC Medicine</i> , 2021, 19, 244.	2.3	9
11	Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis. <i>BMC Medicine</i> , 2021, 19, 315.	2.3	5
12	Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model. <i>Clinical Infectious Diseases</i> , 2020, 71, 2889-2896.	2.9	1
13	Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV. <i>Aids</i> , 2020, 34, 63-71.	1.0	11
14	A clinical score for identifying active tuberculosis while awaiting microbiological results: Development and validation of a multivariable prediction model in sub-Saharan Africa. <i>PLoS Medicine</i> , 2020, 17, e1003420.	3.9	13
15	Evaluation of underweight status may improve identification of the highest-risk patients during outpatient evaluation for pulmonary tuberculosis. <i>PLoS ONE</i> , 2020, 15, e0243542.	1.1	2
16	Title is missing!. , 2020, 17, e1003420.		0
17	Title is missing!. , 2020, 17, e1003420.		0
18	Title is missing!. , 2020, 17, e1003420.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 17, e1003420.		0
20	Title is missing!. , 2020, 17, e1003420.		0
21	Title is missing!., 2020, 15, e0243542.		0
22	Title is missing!. , 2020, 15, e0243542.		0
23	Title is missing!. , 2020, 15, e0243542.		0
24	Title is missing!., 2020, 15, e0243542.		0
25	Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model. BMC Medicine, 2019, 17, 155.	2.3	19
26	Empiric treatment of pulmonary TB in the Xpert era: Correspondence of sputum culture, Xpert MTB/RIF, and clinical diagnoses. PLoS ONE, 2019, 14, e0220251.	1.1	20
27	Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. BMC Infectious Diseases, 2019, 19, 794.	1.3	6
28	Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. Aids, 2019, 33, 525-536.	1.0	7
29	Projecting the impact of variable MDR-TB transmission efficiency on long-term epidemic trends in South Africa and Vietnam. Scientific Reports, 2019, 9, 18099.	1.6	4
30	Impact of nonintrusive clinical decision support systems on laboratory test utilization in a large academic centre. Journal of Evaluation in Clinical Practice, 2018, 24, 474-479.	0.9	12
31	Linking Individual Natural History to Population Outcomes in Tuberculosis. Journal of Infectious Diseases, 2018, 217, 112-121.	1.9	9
32	Would pan-tuberculosis treatment regimens be cost-effective?. Lancet Respiratory Medicine,the, 2018, 6, 486-488.	5.2	5
33	Target regimen profiles for treatment of tuberculosis: a WHO document. European Respiratory Journal, 2017, 49, 1602352.	3.1	25
34	Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases, 2017, 65, 1206-1211.	2.9	13
35	Drug-resistant tuberculosis in 2017: at a crossroads. Lancet Respiratory Medicine,the, 2017, 5, 241-242.	5.2	6
36	Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respiratory Medicine,the, 2017, 5, 191-199.	5.2	23

#	ARTICLE	IF	CITATIONS
37	Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. <i>International Journal of Infectious Diseases</i> , 2017, 56, 185-189.	1.5	14
38	Mathematical Modeling of "Chronic" Infectious Diseases: Unpacking the Black Box. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx172.	0.4	12
39	Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis. <i>Lancet Public Health</i> , The, 2017, 2, e323-e330.	4.7	12
40	Tuberculosis in children: under-counted and under-treated. <i>The Lancet Global Health</i> , 2017, 5, e845-e846.	2.9	9
41	Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study. <i>PLoS Medicine</i> , 2017, 14, e1002472.	3.9	50
42	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. <i>PLoS Medicine</i> , 2017, 14, e1002202.	3.9	20
43	MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. <i>PLoS ONE</i> , 2017, 12, e0172748.	1.1	30
44	Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 963-972.	5.2	165
45	Transforming the Fight Against Tuberculosis: Targeting Catalysts of Transmission. <i>Clinical Infectious Diseases</i> , 2014, 59, 1123-1129.	2.9	37
46	Implementation of GenoType MTBDRplus Reduces Time to Multidrug-Resistant Tuberculosis Therapy Initiation in South Africa. <i>Clinical Infectious Diseases</i> , 2013, 56, 503-508.	2.9	80
47	Alcohol, Hospital Discharge, and Socioeconomic Risk Factors for Default from Multidrug Resistant Tuberculosis Treatment in Rural South Africa: A Retrospective Cohort Study. <i>PLoS ONE</i> , 2013, 8, e83480.	1.1	45
48	Molecular Determinants of Proteolytic Disassembly of the Reovirus Outer Capsid. <i>Journal of Biological Chemistry</i> , 2012, 287, 8029-8038.	1.6	27
49	Medically unexplained illness and the diagnosis of hysterical conversion reaction (HCR) in women's medicine wards of Bangladeshi hospitals: a record review and qualitative study. <i>BMC Women's Health</i> , 2012, 12, 38.	0.8	5
50	Relatedness of <i>Vibrio cholerae</i> O1/O139 Isolates from Patients and Their Household Contacts, Determined by Multilocus Variable-Number Tandem-Repeat Analysis. <i>Journal of Bacteriology</i> , 2010, 192, 4367-4376.	1.0	56
51	Development of Immunoglobulin M Memory to Both a T-Cell-Independent and a T-Cell-Dependent Antigen following Infection with <i>Vibrio cholerae</i> O1 in Bangladesh. <i>Infection and Immunity</i> , 2010, 78, 253-259.	1.0	23
52	Leptospirosis as a Cause of Fever in Urban Bangladesh. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 1127-1130.	0.6	24
53	Memory T-Cell Responses to <i>Vibrio cholerae</i> O1 Infection. <i>Infection and Immunity</i> , 2009, 77, 5090-5096.	1.0	46
54	Antigen-Specific Memory B-Cell Responses to <i>Vibrio cholerae</i> O1 Infection in Bangladesh. <i>Infection and Immunity</i> , 2009, 77, 3850-3856.	1.0	110

#	ARTICLE	IF	CITATIONS
55	Early Neurologic Abnormalities Associated with Human T-Cell Lymphotropic Virus Type 1 Infection in a Cohort of Peruvian Children. <i>Journal of Pediatrics</i> , 2009, 155, 700-706.	0.9	42